8
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome‐driven neoplasms

      1 , 2 , 3 , 4 , 5 , 6 , 7 , 1 , 3 , 8 , 9
      The Journal of Pathology
      Wiley

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Molecular pathological epidemiology (MPE) is an integrative transdisciplinary field that addresses heterogeneous effects of exogenous and endogenous factors (collectively termed “exposures”), including microorganisms, on disease occurrence and consequence utilising molecular pathological signatures of the disease. In parallel with the paradigm of precision medicine, findings from MPE research can provide aetiological insights into tailored strategies of disease prevention and treatment. Due to the availability of molecular pathological tests on tumours, the MPE approach has been utilised predominantly in research on cancers including breast, lung, prostate, and colorectal carcinomas. Mounting evidence indicates that the microbiome (inclusive of viruses, bacteria, fungi, and parasites) plays an important role in a variety of human diseases including neoplasms. An alteration of the microbiome may be not only a cause of neoplasia but also an informative biomarker that indicates or mediates the association of an epidemiological exposure with health conditions and outcomes. To adequately educate and train investigators in this emerging area, we herein propose the integration of microbiology into the MPE model (termed “microbiology-MPE”), which can improve our understanding of the complex interactions of environment, tumour cells, the immune system, and microbes in the tumour microenvironment during the carcinogenic process. Using this approach, we can examine how lifestyle factors, dietary patterns, medications, environmental exposures, and germline genetics influence cancer development and progression through impacting the microbial communities in the human body. Further integration of other disciplines (e.g. pharmacology, immunology, nutrition) into microbiology-MPE would expand this developing research frontier. With the advent of high-throughput next-generation sequencing technologies, researchers now have increasing access to large-scale metagenomics as well as other omics data (e.g. genomics, epigenomics, proteomics, and metabolomics) in population-based research. The integrative field of microbiology-MPE will open new opportunities for personalised medicine and public health.

          Related collections

          Most cited references145

          • Record: found
          • Abstract: found
          • Article: not found

          Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer

          In this Review, Dienstmann et al. analyse the complex nature of colorectal cancer and the different subtypes in which this disease can be classified, advocating for a 'multi-molecular' perspective for the development of therapies to treat it.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine

            Chronic fibrotic liver disease caused by viral or metabolic etiologies is a high-risk condition for developing hepatocellular carcinoma (HCC). Even after complete HCC tumor resection or ablation, the carcinogenic tissue microenvironment in the remnant liver can give rise to recurrent de novo HCC tumors, which progress into incurable, advanced-stage disease in the majority of patients. Thus, early detection and prevention of HCC development is, in principle, the most impactful strategy to improve patient prognosis. However, practice guideline-recommended “one-size-fits-all” HCC screening for early tumor detection is utilized in less than 20% of the target population, and performance of screening modalities, i.e., ultrasound and alpha-fetoprotein is suboptimal. Furthermore, optimal screening strategies for emerging at-risk patient populations such as chronic hepatitis C after viral cure and non-cirrhotic non-alcoholic fatty liver disease remain controversial. New HCC biomarkers and imaging modalities may improve sensitivity and specificity of HCC detection. Clinical and molecular HCC risk scores will enable precise HCC risk prediction followed by tailored HCC screening for individual patients to maximize its cost-effectiveness and optimize allocation of limited medical resources. Several etiology-specific and generic HCC chemoprevention strategies are evolving. Epidemiological and experimental studies have identified candidate chemoprevention targets and therapies, including statins, anti-diabetic drugs, and selective molecular targeted agents, although their clinical testing has been limited by the lengthy process of cancer development that requires long-term, costly studies. Individual HCC risk prediction is expected to overcome the challenge by enabling personalized chemoprevention targeting high-risk patients to achieve precision HCC prevention and substantially improve the dismal prognosis of HCC.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              From tumour heterogeneity to advances in precision treatment of colorectal cancer

              Recent advances in molecular biology and our understanding of the development of colorectal cancer (CRC) has enabled the more-precise use of innovative targeted therapies for this disease. In particular, large databases to capture and store genomic information on causative genes frequently deregulated in CRC, the use of gene-expression profiling to differentiate the subtypes of CRC into prognostic and predictive groups, and results from next-generation sequencing analyses have led to an appreciation of the extensive intratumour heterogeneity of this disease. The authors highlight these advances, place them into clinical context, and present other novel targets and therapeutic opportunities on the horizon.
                Bookmark

                Author and article information

                Journal
                The Journal of Pathology
                J. Pathol.
                Wiley
                0022-3417
                1096-9896
                January 16 2019
                April 2019
                February 20 2019
                April 2019
                : 247
                : 5
                : 615-628
                Affiliations
                [1 ]Department of Oncologic Pathology, Dana‐Farber Cancer Institute and Harvard Medical School Boston, Massachusetts, 02215 USA
                [2 ]Department of Gastroenterology, Graduate School of MedicineThe University of Tokyo Tokyo Japan
                [3 ]Program in MPE Molecular Pathological Epidemiology, Department of PathologyBrigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA
                [4 ]American Society for Clinical Pathology Chicago Illinois USA
                [5 ]Departments of Epidemiology and NutritionHarvard T.H. Chan School of Public Health Boston Massachusetts USA
                [6 ]Clinical and Translational Epidemiology UnitMassachusetts General Hospital and Harvard Medical School Boston Massachusetts USA
                [7 ]Division of GastroenterologyMassachusetts General Hospital and Harvard Medical School Boston Massachusetts USA
                [8 ]Department of EpidemiologyHarvard T.H. Chan School of Public Health Boston Massachusetts USA
                [9 ]Broad Institute of Massachusetts Institute of Technology and Harvard Cambridge Massachusetts USA
                Article
                10.1002/path.5236
                6509405
                30632609
                689dea21-0b0d-4620-92a2-7a28bd3a6692
                © 2019

                http://onlinelibrary.wiley.com/termsAndConditions#vor

                http://doi.wiley.com/10.1002/tdm_license_1.1

                History

                Comments

                Comment on this article